An observational study in Growth Hormone Disorder, Growth Hormone Deficiency in Children and Foetal Growth Problem, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2015-03-30.
Sponsored by Novo Nordisk A/S · Observational
This study is conducted in Europe. The aim of this study is to evaluate safety during the long-term use of somatropin (Norditropin®) in children as well as efficacy on change in height. A subgroup of children small for their gestational age is included.
125 studies on the registry are indexed under Dwarfism; 19 are open to participants now.
This study's enrollment of 5,442 is above the median of 100 across 44 observational studies indexed under Dwarfism.
Browse Dwarfism studies →Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 101 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Children treated with somatropin
Inclusion Criteria:
Drug: somatropin
Prescribed at the discretion of the treating physician according to product labelling
Number of adverse events
Time frame: Up to 10 years
Number of patients continuing somatropin treatment
Time frame: Up to 10 years
Change in height
Time frame: Up to 10 years
Onset of puberty in children small for gestational age
Time frame: Up to 10 years
Co-morbidities in children small for gestational age
Time frame: Up to 10 years
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S